First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (neo)adjuvant trastuzumab

被引：0

作者：

Vaglica, M. ^{[1
]}

Lambertini, M. ^{[2
]}

Ferreira, A. ^{[3
]}

Poggio, F. ^{[2
]}

Puglisi, F. ^{[4
]}

Sottotetti, F. ^{[5
]}

Montemurro, F. ^{[6
]}

Poletto, E. ^{[4
]}

Pozzi, E. ^{[5
]}

Risi, E. ^{[7
]}

Lai, A. ^{[8
]}

Zanardi, E. ^{[9
]}

Sini, V. ^{[10
]}

Ziliani, S. ^{[11
]}

Minuti, G. ^{[12
]}

Mura, S. ^{[13
]}

Grasso, D. ^{[14
]}

Ferrarini, I. ^{[15
]}

Pronzato, P. ^{[2
]}

Del Mastro, L. ^{[1
]}

机构：

[1] IRCCS AOU San Martino IST, Med Oncol, UO Sviluppo Terapie Innovat, Genoa, Italy

[2] IRCCS AOU San Martino IST, UO Oncol Med 2, Genoa, Italy

[3] Hosp Santa Maria, Inst Med Mol, Lisbon, Portugal

[4] Univ Hosp, Oncol, Udine, Italy

[5] Fdn Maugeri IRCCS, Med Oncol, Pavia, Italy

[6] Fdn Piemonte Oncol, Ist Candiolo IRCCS, Unit Invest Clin Oncol, Candiolo Torino, Italy

[7] Univ Roma La Sapienza, Radiol Oncol & Human Pathol, Oncol Unit B, I-00185 Rome, Italy

[8] Azienda Osped Univ, Med Oncol, Sassari, Italy

[9] IRCCS AOU San Martino IST, Med Oncol, Clin Oncol Med, Genoa, Italy

[10] Univ Roma La Sapienza, St Andrea Hosp, Oncol, I-00185 Rome, Italy

[11] Osped San Paolo, Med Oncol, Savona, Italy

[12] Civil Hosp, Ist Tumori Toscano, Med Oncol, Livorno, Italy

[13] Osped Santissima Annunziata, Oncol, Sassari, Italy

[14] IRCCS San Matteo Univ Hosp Fdn, Med Oncol, Pavia, Italy

[15] Azienda Osped Univ Pisana, Polo Oncol, Pisa, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)30813-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1863

引用

页码：S286 / S286

页数：1

共 50 条

[31] Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer
Rastogi, Priya
Davidson, Nancy E.
ONKOLOGIE, 2010, 33 (8-9): : 420 - 421
[32] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
Lorenz, Judith
GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
[33] Efficacy of trastuzumab-based therapy after disease progression on lapatinib based therapy in heavily pretreated HER2-positive metastatic breast cancer patients.
Uncu, Dogan
Bayoglu, Ibrahim Vedat
Arslan, Ulku Yalcintas
Kucukoner, Mehmet
Artac, Mehmet
Koca, Dogan
Oguz, Arzu
Demirci, Umut
Arpaci, Erkan
Dogan, Mutlu
Kucukzeybek, Yuksel
Turker, Ibrahim
Isikdogan, Abdurrahman
Guler, Tunc
Zengin, Nurullah
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[34] Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?
Santini, Daniele
Vincenzi, Bruno
Tonini, Giuseppe
WOMENS HEALTH, 2006, 2 (01) : 1 - 3
[35] Paclitaxel, Carboplatin, and Trastuzumab in a Neo-adjuvant Regimen for HER2-positive Breast Cancer
Sonke, Gabe S.
Mandjes, Ingrid A.
Holtkamp, Marjo J.
Schot, Margaret
van Werkhoven, Erik
Wesseling, Jelle
Peeters, Marie-Jeanne Vrancken
Rodenhuis, Sjoerd
Linn, Sabine C.
BREAST JOURNAL, 2013, 19 (04): : 419 - 426
[36] TRASTUZUMAB-BASED THERAPY AFTER DISEASE PROGRESSION FOLLOWING LAPATINIB AND CAPECITABINE IN HER2-POSITIVE (HER2+) METASTATIC BREAST CANCER (MBC)
Metro, G.
Fabi, A.
Foglietta, J.
Russillo, M.
Stocchi, L.
Crino, L.
Papaldo, P.
Sperduti, I.
Cognetti, F.
Gori, S.
ANNALS OF ONCOLOGY, 2010, 21 : 100 - 101
[37] Continued trastuzumab therapy for patients with HER2-positive breast cancer
Haslbauer, F.
EJC SUPPLEMENTS, 2008, 6 (07): : 221 - 221
[38] Trastuzumab Rechallenge After Lapatinib- and Trastuzumab-Resistant Disease Progression in HER2-Positive Breast Cancer
Araki, Kazuhiro
Fukada, Ippei
Horii, Rie
Takahashi, Shunji
Akiyama, Futoshi
Iwase, Takuji
Ito, Yoshinori
CLINICAL BREAST CANCER, 2015, 15 (06) : 432 - 439
[39] Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
Iwata, Hiroji
Xu, Binghe
Kim, Sung-Bae
Chung, Wei-Pang
Park, Yeon Hee
Kim, Min Hwan
Tseng, Ling-Ming
Chung, Chi-Feng
Huang, Chiun-Sheng
Kim, Jee Hyun
Chiu, Joanne Wing Yan
Yamashita, Toshinari
Li, Wei
Egorov, Anton
Nishijima, Soichiro
Nakatani, Shunsuke
Nishiyama, Yuji
Sugihara, Masahiro
Cortes, Javier
Im, Seock-Ah
CANCER SCIENCE, 2024, 115 (09) : 3079 - 3088
[40] First line trastuzumab-based therapy in her2-positive metastatic breast cancer patients presenting with de novo or recurrent disease
D'Alonzo, A.
Lambertini, M.
Ferreira, A.
Poggia, F.
Puglisi, F.
Sottotetti, F.
Poletto, E.
Pozzi, E.
Risi, E.
Lai, A.
Dellepiane, C.
Sini, V.
Ziliani, S.
Minuti, G.
Mura, S.
Grasso, D.
Fancelli, S.
Pronzato, P.
Del Mastro, L.
ANNALS OF ONCOLOGY, 2015, 26 : 10 - 10

← 1 2 3 4 5 →